Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (37529)	3/5/2002 2:52:40 PM
From: Frederick Langford	Read Replies (1) \| Respond to of 99280

Zeev, It's hard to turn loose of a company that has numbers like this: From 2/21 Taro Pharmaceuticals Reports Record 2001 Results -- 24 Consecutive Quarters of Record Sales, 14 Consecutive Quarters of Record Net Income Business Editors HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 21, 2002--Taro Pharmaceutical Industries Ltd. (NASDAQ/NMS: TARO)-- 2001 Highlights - Q4 Sales Increase 47% to $44,013,000 - Q4 Gross Profit Increases 58% to $28,459,000 - Q4 Net Income Increases 180% to $9,826,000, or $0.34 per Diluted Share - 2001 Sales Increase 45% to $150,134,000 - 2001 Net Income Increases 159% to $25,994,000, or $0.99 per Diluted Share - Taro Closed Public Offering of 5,750,000 Ordinary Shares in Q4 2001 Fred